Global gene expression profiling defines an ERBB2 molecular subtype of BC that predominantly consists of estrogen receptor (ER) negative HER2+ tumors (HER2+/ER-) [15,16], while HER2+/ER+ tumors are more heterogeneously classified. Here, ERBB2 is linked to breast cancer.